دورية أكاديمية
Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care.
| العنوان: | Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care. |
|---|---|
| المؤلفون: | Roberts A; Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. amanda.roberts@sunnybrook.ca.; Sunnybrook Research Institute, 2075 Bayview Ave, T2-063, Toronto, ON, M4N 3M5, Canada. amanda.roberts@sunnybrook.ca., Hallet J; Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Sunnybrook Research Institute, 2075 Bayview Ave, T2-063, Toronto, ON, M4N 3M5, Canada., Nguyen L; ICES, Toronto, ON, Canada., Coburn N; Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Sunnybrook Research Institute, 2075 Bayview Ave, T2-063, Toronto, ON, M4N 3M5, Canada.; ICES, Toronto, ON, Canada., Wright FC; Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Sunnybrook Research Institute, 2075 Bayview Ave, T2-063, Toronto, ON, M4N 3M5, Canada., Gandhi S; Sunnybrook Research Institute, 2075 Bayview Ave, T2-063, Toronto, ON, M4N 3M5, Canada.; Department of Medicine, Sunnybrook Health Science Centre, Toronto, ON, Canada., Jerzak K; Sunnybrook Research Institute, 2075 Bayview Ave, T2-063, Toronto, ON, M4N 3M5, Canada.; Department of Medicine, Sunnybrook Health Science Centre, Toronto, ON, Canada., Eisen A; Sunnybrook Research Institute, 2075 Bayview Ave, T2-063, Toronto, ON, M4N 3M5, Canada.; Department of Medicine, Sunnybrook Health Science Centre, Toronto, ON, Canada., Look Hong NJ; Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Sunnybrook Research Institute, 2075 Bayview Ave, T2-063, Toronto, ON, M4N 3M5, Canada.; ICES, Toronto, ON, Canada. |
| المصدر: | Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jul; Vol. 206 (2), pp. 227-244. Date of Electronic Publication: 2024 Apr 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Dordrecht : Kluwer Academic Original Publication: The Hague ; Boston : M. Nijhoff, c1981- |
| مواضيع طبية MeSH: | Neoadjuvant Therapy*/methods , Receptor, ErbB-2*/metabolism , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/pathology, Humans ; Female ; Middle Aged ; Retrospective Studies ; Adult ; Aged ; Standard of Care ; Chemotherapy, Adjuvant/methods ; Ontario/epidemiology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Staging ; Prognosis ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Breast Neoplasms/metabolism |
| مستخلص: | Purpose: Neoadjuvant chemotherapy (NAC) for triple-negative (TN) and Her2-positive (HER2) breast cancers is supported by international guidelines as it can decrease extent of surgery, provide prognostic information, and allow response-driven adjuvant therapies. Our goal was to describe practice patterns for patients with TN and HER2-positive breast cancer and identify the factors associated with the receipt of NAC versus surgery as initial treatment. Methods: A retrospective population-based cohort study of adult women diagnosed with stage I-III TN or HER2-positive breast cancer (2012-2020) in Ontario was completed using linked administrative datasets. The primary outcome was NAC as first treatment. The association between NAC and patient, tumor, and practice-related factors was examined using multivariable logistic regression models. Results: Of 14,653 patients included, 23.9% (n = 3500) underwent NAC as first treatment. Patients who underwent NAC were more likely to be younger and have larger tumors, node-positive disease, and stage 3 disease. Of patients who underwent surgery first, 8.8% were seen by a medical oncologist prior to surgery. On multivariable analysis, increasing tumor size (T2 vs T1/T0: 2.75 (2.31-3.28)) and node-positive (N1 vs N0: OR 3.54 (2.92-4.30)) disease were both associated increased odds of receiving NAC. Conclusion: A considerable proportion of patients with TN and HER2-positive breast cancer do not receive NAC as first treatment. Of those, most were not assessed by both a surgeon and medical oncologist prior to initiating therapy. This points toward potential gaps in multidisciplinary assessment and disparities in receipt of guideline-concordant care. (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr 30:96–102. https://doi.org/10.1093/oxfordjournals.jncimonographs.a003469. (PMID: 10.1093/oxfordjournals.jncimonographs.a003469) Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21(22):4165–4174. https://doi.org/10.1200/JCO.2003.12.005. (PMID: 10.1200/JCO.2003.12.00514559892) Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455–1461. https://doi.org/10.1001/jama.2013.278932. (PMID: 10.1001/jama.2013.278932241011694075763) Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33(3):258–264. https://doi.org/10.1200/JCO.2014.55.7827. (PMID: 10.1200/JCO.2014.55.782725452445) Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS (2018) Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat 170(3):559–567. https://doi.org/10.1007/s10549-018-4801-3. (PMID: 10.1007/s10549-018-4801-329693228) von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804. https://doi.org/10.1200/JCO.2011.38.8595. (PMID: 10.1200/JCO.2011.38.8595) Fallahpour S, Navaneelan T, De P, Borgo A (2017) Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open 5(3):E734–E739. https://doi.org/10.9778/cmajo.20170030. (PMID: 10.9778/cmajo.20170030289514455621954) Masuda N, Lee SJ, Ohtani S et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159. https://doi.org/10.1056/NEJMoa1612645. (PMID: 10.1056/NEJMoa161264528564564) Von Minckwitz G, Huang CS, Mano MS et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617–628. https://doi.org/10.1056/NEJMoa1814017. (PMID: 10.1056/NEJMoa1814017) Gandhi S, Brackstone M, Hong NJL et al (2022) A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. Breast Cancer Res Treat 193(1):1–20. https://doi.org/10.1007/s10549-022-06522-6. (PMID: 10.1007/s10549-022-06522-6352247138993711) Korde LA, Somerfield MR, Carey LA et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39(13):1485–1505. https://doi.org/10.1200/JCO.20.03399. (PMID: 10.1200/JCO.20.03399335078158274745) Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(8):1194–1220. https://doi.org/10.1093/annonc/mdz173. (PMID: 10.1093/annonc/mdz17331161190) NICE 2018. Early and locally advanced breast cancer: diagnosis and management. https://www.nice.org.uk/guidance/ng101 /resources/early-and-locally-advanced-breast-cancer-diagnosis- and-management-pdf-66141532914901. Brezden-Masley C, Fathers KE, Coombes ME, Pourmirza B, Xue C, Jerzak KJ (2020) A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer. Cancer Med 9(20):7548–7557. https://doi.org/10.1002/cam4.3038. (PMID: 10.1002/cam4.3038328625017571809) Brezden-Masley C, Fathers KE, Coombes ME, Pourmirza B, Xue C, Jerzak KJ (2021) A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer. Breast Cancer Res Treat 185(3):807–815. https://doi.org/10.1007/s10549-020-05976-w. (PMID: 10.1007/s10549-020-05976-w33090268) Mougalian SS, Soulos PR, Killelea BK et al (2015) Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 121(15):2544–2552. https://doi.org/10.1002/cncr.29348. (PMID: 10.1002/cncr.2934825902916) Mohiuddin JJ, Deal AM, Carey LA et al (2016) Neoadjuvant systemic therapy use for younger patients with breast cancer treated in different types of cancer centers across the United States. J Am Coll Surg 223(5):717-728.e4. https://doi.org/10.1016/j.jamcollsurg.2016.08.541. (PMID: 10.1016/j.jamcollsurg.2016.08.541277888946059614) Whitehead I, Irwin GW, Bannon F et al (2021) The NeST (Neoadjuvant systemic therapy in breast cancer) study: National practice questionnaire of United Kingdom multi-disciplinary decision making. BMC Cancer 21(1):90. https://doi.org/10.1186/s12885-020-07757-6. (PMID: 10.1186/s12885-020-07757-6334827707825231) Spronk PER, Volders JH, van den Tol P, Smorenburg CH, Vrancken Peeters MJTFD (2019) Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch breast cancer audit. Eur J Surg Oncol 45(2):110–117. https://doi.org/10.1016/j.ejso.2018.09.027. (PMID: 10.1016/j.ejso.2018.09.02730348601) Benchimol EI, Smeeth L, Guttmann A et al (2015) The reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med 12(10):e1001885. https://doi.org/10.1371/journal.pmed.1001885. (PMID: 10.1371/journal.pmed.1001885264408034595218) Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I (2013) Guidelines on person-level costing using administrative databases in Ontario. Mittmann N, Seung S, Cheng S et al (2015) Generating costing algorithms for oncology drugs using administrative databases. Value in Health 18(7):A691. https://doi.org/10.1016/j.jval.2015.09.2568. (PMID: 10.1016/j.jval.2015.09.2568) Mittmann N, Cheng SY, Liu N et al (2019) The generation of two specific cancer costing algorithms using Ontario administrative databases. Curr Oncol 26(5):e682–e692. https://doi.org/10.3747/co.26.5279. (PMID: 10.3747/co.26.5279317086616821127) Mavros MN, Coburn NG, Davis LE et al (2019) Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. CMAJ 191(21):E574–E580. https://doi.org/10.1503/cmaj.190211. (PMID: 10.1503/cmaj.190211311336046538499) Schroeder MC, Chapman CG, Nattinger MC et al (2016) Variation in geographic access to chemotherapy by definitions of providers and service locations: a population-based observational study. BMC Health Serv Res 16:274. https://doi.org/10.1186/s12913-016-1549-5. (PMID: 10.1186/s12913-016-1549-5274306234950719) Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8–27. https://doi.org/10.1097/00005650-199801000-00004. (PMID: 10.1097/00005650-199801000-000049431328) Kralji B (2000) Measuring, “rurality” for purposes of health-care planning: an empirical measure for Ontario. Ont Med Rev 67:33–52. Health Quality Ontario. Geographic Location Methods Review: Summary Report. https://www.hqontario.ca/Portals/0/documents/pr/hqo-geographic-location-methods-review-report.pdf . Matheson FI, Moloney G, van Inge T. 2016 Ontario Marginalization Index User Guide. Tøge AG, Bell R (2016) Material deprivation and health: a longitudinal study. BMC Public Health 16:747. https://doi.org/10.1186/s12889-016-3327-z. (PMID: 10.1186/s12889-016-3327-z275019624977874) Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (2010) AJCC Cancer Staging Manual. 7th ed. Springer. Hortobagyi G, Connolly J. AJCC Cancer Staging Manual (2016) 8th ed. (Amin M, Edge S, Greene F, et al, eds.) Springer International Publisher. Cancer Care Ontario: Regional Cancer Centres https. https://www.cancercareontario.ca/en/find-cancer-services/regional-cancer-centres/list . Austin PC (2009) Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 38(6):1228–1234. https://doi.org/10.1080/03610910902859574. (PMID: 10.1080/03610910902859574) Ballinger GA (2004) Using generalized estimating equations for longitudinal data analysis. Organ Res Methods 7(2):127–150. https://doi.org/10.1177/1094428104263672. (PMID: 10.1177/1094428104263672) Riedel F, Hoffmann AS, Moderow M et al (2020) Time trends of neoadjuvant chemotherapy for early breast cancer. Int J Cancer 147(11):3049–3058. https://doi.org/10.1002/ijc.33122. (PMID: 10.1002/ijc.3312232468577) Powis M, Groome P, Biswanger N et al (2019) Cross-Canada differences in early-stage breast cancer treatment and acute-care use. Curr Oncol 26(5):624–639. https://doi.org/10.3747/co.26.5003. (PMID: 10.3747/co.26.5003) Yee EK, Coburn NG, Zuk V et al (2021) Geographic impact on access to care and survival for non-curative esophagogastric cancer: a population-based study. Gastric Cancer 24(4):790–799. https://doi.org/10.1007/s10120-021-01157-w. (PMID: 10.1007/s10120-021-01157-w33550518) Yee EK, Coburn NG, Davis LE et al (2020) Impact of geography on care delivery and survival for noncurable pancreatic adenocarcinoma: a population-based analysis. J Natl Compr Canc Netw 18(12):1642–1650. https://doi.org/10.6004/jnccn.2020.7605. (PMID: 10.6004/jnccn.2020.760533285520) |
| فهرسة مساهمة: | Keywords: Breast; Chemotherapy; Her2 positive; Neoadjuvant; Triple negative |
| المشرفين على المادة: | EC 2.7.10.1 (Receptor, ErbB-2) EC 2.7.10.1 (ERBB2 protein, human) |
| تواريخ الأحداث: | Date Created: 20240427 Date Completed: 20240617 Latest Revision: 20240703 |
| رمز التحديث: | 20240703 |
| DOI: | 10.1007/s10549-024-07282-1 |
| PMID: | 38676808 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1573-7217 |
|---|---|
| DOI: | 10.1007/s10549-024-07282-1 |